132
Views
5
CrossRef citations to date
0
Altmetric
Original Articles

Patients with suspected benign tumors and glial fibrillary acidic protein autoantibody: an analysis of five cases

, , , , , , , & show all
Pages 1183-1188 | Received 05 Jul 2018, Accepted 11 Jul 2019, Published online: 15 Aug 2019

References

  • Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73:1297–1307.
  • Long Y, Liang J, Xu H, et al. Autoimmune glial fibrillary acidic protein astrocytopathy in Chinese patients: a retrospective study. Eur J Neurol. 2018;25:477–483.
  • Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81:298–309.
  • Iorio R, Damato V, Evoli A, et al. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry. 2018;89:138–146.
  • Talarico LR, Schatzberg SJ. Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: a review and future perspectives. J Small Anim Pract. 2010;51:138–149.
  • Munana KR, Luttgen PJ. Prognostic factors for dogs with granulomatous meningoencephalomyelitis: 42 cases (1982–1996). J Am Vet Med Assoc. 1998;212:1902–1906.
  • Matsuki N, Fujiwara K, Tamahara S, et al. Prevalence of autoantibody in cerebrospinal fluids from dogs with various CNS diseases. J Vet Med Sci. 2004;66:295–297.
  • Toda Y, Matsuki N, Shibuya M, et al. Glial fibrillary acidic protein (GFAP) and anti-GFAP autoantibody in canine necrotising meningoencephalitis. Vet Rec. 2007;161:261–264.
  • McCall MA, Gregg RG, Behringer RR, et al. Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci USA. 1996;93:6361–6366.
  • Yang X, Liang J, Huang Q, et al. Treatment of autoimmune glial fibrillary acidic protein astrocytopathy: follow-up in 7 cases. Neuroimmunomodulation. 2017;24:113–119.
  • Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–165.
  • Yao Y, Peng B, Wang XH, et al. [Analysis of prodromal phase and prodromal events in anti-N-methyl-D-aspartate receptor encephalitis]. Zhonghua Yi Xue Za Zhi. 2017;97:1469–1473.
  • Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
  • Day GS, Laiq S, Tang-Wai DF, et al. Abnormal neurons in teratomas in NMDAR encephalitis. JAMA Neurol. 2014;71:717–724.
  • Zekeridou A, McKeon A, Flanagan EP. A path to understanding autoimmune GFAP astrocytopathy. Eur J Neurol. 2018;25:421–422.
  • Li J, Xu Y, Ren H, et al. Autoimmune GFAP astrocytopathy after viral encephalitis: a case report. Mult Scler Relat Disord. 2018;21:84–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.